RLSD09 [Anti-PA 3, DB90 5CT3.5.2]細胞
運輸方式： 凍存運輸
細胞形態： **樣
**類型： IgG1
數量： 大量
是否是腫瘤細胞： 0
物種來源： 小鼠
ATCC Number： HB-8525?
生長狀態： 懸浮生長
RLSD09 [Anti-PA 3, DB90 5CT3.5.2]細胞Designations: RLSD09 [Anti-PA 3, DB90 5CT3.5.2]
Depositors: Cetus Corp.
Isotype: IgG1
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Source: Cell Type: RLSD09 [Anti-PA 3, DB90 5CT3.5.2]細胞hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human prostate antigen (PA, 33000 dalton glycoprotein)
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Comments: Animals were immunized with purified PA from human semen.
Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
Propagation: RLSD09 [Anti-PA 3, DB90 5CT3.5.2]細胞ATCC complete growth medium: The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water and supplemented with 1.5 g/L sodium bicarbonate. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: fetal bovine serum, 90%; DMSO, 10%
References: 3896: M'Timkulu T, et al. RLSD09 [Anti-PA 3, DB90 5CT3.5.2]細胞Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay. US Patent 4,690,890 dated Sep 1 1987
